Finasteride Tablets

Finasteride is a synthetic steroidal compound that is a specific inhibitor of the intracellular enzyme type II 5alpha;-reductase in the process of metabolizing the androgen testosterone to dihydrotestosterone. Finasteride has no affinity for androgen receptors and has no androgenic, anti-androgenic, estrogenic, anti-estrogenic or progestational effects. Inhibition of this enzyme can hinder the conversion of testosterone to the androgen dihydrotestosterone in peripheral tissues, resulting in the conversion of dihydrotestosterone in serum and tissues, and significantly reducing the concentration of dihydrotestosterone in serum and tissues. Compared with placebo, it can increase the level of testosterone in the blood circulation by about 10-15%, but it is still within the physiological range. Finasteride can rapidly reduce the concentration of dihydrotestosterone in serum, and significantly reduce it within 24 hours after administration. Type II 5alpha;-reductase is contained in hair follicles. In the bald areas of patients with male pattern baldness, the hair follicles in the scalp become smaller and dihydrotestosterone increases. Administration of finasteride can reduce the concentration of dihydrotestosterone in the scalp and serum of these patients. Men who are congenitally deficient in type II 5alpha;-reductase will not suffer from male pattern baldness. These data and the results of clinical studies confirm that finasteride can inhibit the shrinkage of scalp hair follicles and reverse the process of hair loss.

The main ingredient of this product is finasteride, and its chemical name is: N-(1,1-dimethylethyl)-3-oxo(15,17)-4-azaandrost-1-ene-17-amide.

This product is a film-coated tablet, which appears white or off-white after removing the film coating.

Treats male pattern baldness (androgenetic alopecia), promoting hair growth and preventing further hair loss.

The recommended dose is 1 tablet (1 mg) once a day, with or without food. Generally, the effects of increased hair growth, increased hair count and/or prevention of further hair loss can only be observed after continuous use for 3 months or more. Continuous use is recommended to achieve the maximum therapeutic effect. The therapeutic effect can be reversed within 12 months after stopping the medication.

The drug is generally well tolerated, and side effects are usually mild, so treatment generally does not need to be discontinued. In a series of clinical studies involving more than 3,200 male patients, the safety of finasteride in the treatment of alopecia was evaluated. In three 12-month, placebo-controlled, double-blind studies involving multiple research centers, the safety of this product was similar to that of placebo. 1.7% of the 945 male patients treated with this product discontinued treatment due to adverse reactions, while 2.1% of the 934 male patients treated with placebo discontinued treatment due to adverse reactions. In these studies, 1% of male patients treated with this product experienced the following medication-related adverse reactions: decreased libido (1.8% for this product, 1.3% for placebo) and impotence (1.3% for this product, 0.7% for placebo). In addition, 0.8% of male patients treated experienced a decrease in ejaculation volume, compared with 0.4% in the placebo control group. These adverse reactions disappeared after treatment was discontinued, and many patients also had these adverse reactions disappear on their own during continued medication. In another study, the effect of this drug on ejaculation volume was tested and found to be no different from placebo. In patients who used this drug for 5 years, the incidence of the above side effects was reduced to 0.3% (smaller than orequalto). The adverse events reported after marketing are as follows: abnormal ejaculation, breast tenderness and swelling, allergic reactions (including rash, itching, urticaria and lip swelling) and testicular pain.

Pregnant women or women who may become pregnant; those who are allergic to any ingredient of this product are prohibited from using it. It is not suitable for women and children.

Precautions for children: This product is not suitable for children. Precautions for pregnancy and lactation: This product is contraindicated for women who are pregnant or may become pregnant. Precautions for the elderly: No clinical studies have been conducted on the use of finasteride in the treatment of male pattern baldness in elderly male patients.

No important drug interactions have been found clinically. Finasteride does not affect the drug-metabolizing enzyme system related to cytochrome P450. Drugs that have been studied in men include antipyrine, digoxin, glyburide, propranolol, theophylline and warfarin, and no interactions have been found. Although specific interaction studies have not been conducted, in clinical studies, no important adverse interactions have been found when finasteride at a dose of 1 mg or more is used in combination with angiotensin-converting enzyme inhibitors, acetaminophen, alpha-receptor blockers, benzodiazepines, beta-receptor blockers, calcium channel blockers, nitrates, diuretics, H2 receptor antagonists, beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors, prostaglandin synthetase inhibitors and quinolones.

Store at 15-30℃. Keep sealed and avoid moisture. The validity period is tentatively 12 months.

1mg

24 months

Topfond Pharmaceutical Co., Ltd.

• Founded in:

  2013-11-13

• Address:

  No. 2 Guangming Road, Yicheng District, Zhumadian City

• Tax NO.:

  91411700083473072R

• Registered Funds:

  420 million yuan

• Website:

  Log in to view

• Email:

  Log in to view